Total Knee ArthroplastyNCT03289247
Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty
A study testing tissue adhesive (Leukosan®) in people with Total Knee Arthroplasty and Infection, run by Hvidovre University Hospital.
Trial summary
The study's primary objective is to compare the following parameters between wound closure following primary TKA with and without supplement tissue adhesive (Leukosan®): Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Total Knee Arthroplasty, Infection, Arthroplasty Complications
- What is being tested?
- tissue adhesive (Leukosan®)
- Type of treatment
- Pill or oral medicine, Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2015to 31 Dec 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient > 18 years of age.
- Patients determined to be suitable for primary simultaneous bilateral TKA based on physical exam and medical history including the following:
- o Osteoarthritis (OA)
- Patient is skeletally mature.
- Patient is willing and able to provide written informed consent.
- Participants must be able to speak and understand Danish
- Patient is willing and able to cooperate in the required post-operative therapy.
- Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
Who cannot join
- Patients with previous open knee surgery on either knee (i.e., osteotomy, unicompartemental arthroplasty, osteosynthesis)
- Patients with previous major trauma to either knee resulting in deformity og scarring.
- Patients receiving treatment for DVT or PE postoperatively.
- Patients with known allergy to skin adhesives
About this study
Official title: A Prospective Single-blinded Randomized Controlled Study Evaluating Efficacy of Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty
The study's primary objective is to compare the following parameters between wound closure following primary TKA with and without supplement tissue adhesive (Leukosan®):
Read the detailed description
Prolonged wound drainage following total joint replacement surgery has been shown to be a predictor of Periprosthetic Joint Infection (PJI) 1-3. Several studies have highlighted this subject, and estimates of the risk of postoperative infection range from 1.3% to 50% among patients with persistent wound drainage 4. Such infections can be one of the most challenging complications following joint replacement surgery and is one of the leading causes of revision surgery following primary hip and knee arthroplasty 5,6.
Several patient-related factors have been associated with delayed wound healing and increased risk of infection following joint replacement surgery. Obesity 4,7, diabetes 8, smoking 9,10 and autoimmune disease 11 have been shown to have a detrimental effect on wound healing. Recently there has also been reports that patients with hypertension 12 have impaired wound healing following total hip arthroplasty (THA) and total knee arthroplasty (TKA).
Surgery related factors such as surgical approach, pneumatic tourniquet time and use of peri-articular local anesthesia have also been shown to have an effect on postoperative wound oozing 9,13.
Finally, several pharmacological factors, such as thromboembolic chemoprophylaxis 4, steroid treatment 9,14 and possibly statins 15,16 might also influence wound healing.
In recent years tissue adhesives for wound closure have been introduced as a replacement or a supplement to conventional closure techniques. Currently very few studies investigate the effect of such tissue adhesives in Total Knee Arthroplasty, and high quality randomized controlled trials (RCT) are lacking.
In this project we wish to:
Evaluate the effect of supplemental wound closure using a high viscosity tissue adhaesive (Leukosan®) in primary TKA with respect to postoperative wound drainage and wound healing.
This project is carried out as a randomized single-blinded controlled trial, in which the clinical outcomes after wound closure following primary bilateral simultaneous TKA with either 1) standard 3-layer closure methods with skin staples or 2) 3-layer closure methods with skin staples supplemented with tissue adhesive (Leukosan®) are compared.
After written informed consent is obtained patients scheduled for a primary bilateral simultaneous TKA will be enrolled in this study and left knee will be randomized to receive either 1) standard 3-layer closure methods with skin staples or 2) 3-layer closure methods with skin staples supplemented with tissue adhesive (Leukosan®), with the opposite treatment on the contralateral knee. All patients will receive AGC total knee prosthesis in both knees (department standard). The standard 3-layer closure consist of: size 2 coated VICRYL® Plus Antibacterial suture for capsule closure, size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and stainless steel staples using PROXIMATE® Fixed-Head stapler for cutaneous closure. Wound oozing will be assessed by project nurses during postoperative day 1-3 as well as patient reported wound oozing on postoperative day 3-21. Wound healing will be assessed using ASEPSIS 17,18 score 3 weeks postoperatively.
Range of motion (ROM) will also be recorded at 3 months postoperatively. Allocation of the participants to one of the two treatment groups is done intraoperatively after initial incision has been made. Participants as well as the research coordinator handling the collected questionnaires postoperatively and evaluating wound healing are all unaware of which method was used for skin closure.
Recruitment of participants to this project is expected to begin in September 2015 or as soon as permission from the Regional Ethics Committee and the Danish Data Protections Agency is obtained. A total of 30 participants are to be included at our institution. Recruitment is expected completed after a maximum period of 1.5 years. The project is expected to be completed 1 year after recruitment of the last participant (2018).
- Being tested
- tissue adhesive (Leukosan®)
- Medical subject headings
- Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tissue adhesive (Leukosan®)Device
Tissue ahaesive
| Study group | Role | What they receive |
|---|---|---|
| Regular | No intervention | Regular closure: The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. |
| Additional tissue adhaesive | Experimental | The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds Receives: Device: tissue adhesive (Leukosan®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wound discharge during stay
The wound will be defined as actively oozing, if the standard bandage Mepilex Border Post-op®, is soaked to the border. Bandages soaked to the border will be replaced. Number of replaced bandages for each knee will be recorded.
Measured: 3 days post op
Secondary outcomes (1)
ASEPSIS score
Wound healing score
Measured: 3 weeks post op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2017
- Study start1 Sep 2015
- Primary completion21 Dec 2017
- Study completion31 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Total Knee ArthroplastyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hvidovre University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kirill Gromov, Hvidovre University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03289247
- Sponsor's protocol ID
- HVH-SBTKA-Adhaesive
- Status last verified
- Jan 2019
- First submitted
- 18 Sep 2017
- Last updated
- 25 Jan 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single-blinded Randomized Controlled Study Evaluating Efficacy of Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty
- ClinicalTrials.gov ID
- NCT03289247
- Acronym / sponsor ID
- HVH-SBTKA-Adhaesive
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Hvidovre University HospitalUniversity, hospital or other
- Study start
- 1 Sep 2015 (actual)
- Primary completion
- 21 Dec 2017 (actual)
- Study completion
- 31 Dec 2018 (actual)
- First posted
- 20 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study's primary objective is to compare the following parameters between wound closure following primary TKA with and without supplement tissue adhesive (Leukosan®):
Detailed description
Prolonged wound drainage following total joint replacement surgery has been shown to be a predictor of Periprosthetic Joint Infection (PJI) 1-3. Several studies have highlighted this subject, and estimates of the risk of postoperative infection range from 1.3% to 50% among patients with persistent wound drainage 4. Such infections can be one of the most challenging complications following joint replacement surgery and is one of the leading causes of revision surgery following primary hip and knee arthroplasty 5,6.
Several patient-related factors have been associated with delayed wound healing and increased risk of infection following joint replacement surgery. Obesity 4,7, diabetes 8, smoking 9,10 and autoimmune disease 11 have been shown to have a detrimental effect on wound healing. Recently there has also been reports that patients with hypertension 12 have impaired wound healing following total hip arthroplasty (THA) and total knee arthroplasty (TKA).
Surgery related factors such as surgical approach, pneumatic tourniquet time and use of peri-articular local anesthesia have also been shown to have an effect on postoperative wound oozing 9,13.
Finally, several pharmacological factors, such as thromboembolic chemoprophylaxis 4, steroid treatment 9,14 and possibly statins 15,16 might also influence wound healing.
In recent years tissue adhesives for wound closure have been introduced as a replacement or a supplement to conventional closure techniques. Currently very few studies investigate the effect of such tissue adhesives in Total Knee Arthroplasty, and high quality randomized controlled trials (RCT) are lacking.
In this project we wish to:
Evaluate the effect of supplemental wound closure using a high viscosity tissue adhaesive (Leukosan®) in primary TKA with respect to postoperative wound drainage and wound healing.
This project is carried out as a randomized single-blinded controlled trial, in which the clinical outcomes after wound closure following primary bilateral simultaneous TKA with either 1) standard 3-layer closure methods with skin staples or 2) 3-layer closure methods with skin staples supplemented with tissue adhesive (Leukosan®) are compared.
After written informed consent is obtained patients scheduled for a primary bilateral simultaneous TKA will be enrolled in this study and left knee will be randomized to receive either 1) standard 3-layer closure methods with skin staples or 2) 3-layer closure methods with skin staples supplemented with tissue adhesive (Leukosan®), with the opposite treatment on the contralateral knee. All patients will receive AGC total knee prosthesis in both knees (department standard). The standard 3-layer closure consist of: size 2 coated VICRYL® Plus Antibacterial suture for capsule closure, size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and stainless steel staples using PROXIMATE® Fixed-Head stapler for cutaneous closure. Wound oozing will be assessed by project nurses during postoperative day 1-3 as well as patient reported wound oozing on postoperative day 3-21. Wound healing will be assessed using ASEPSIS 17,18 score 3 weeks postoperatively.
Range of motion (ROM) will also be recorded at 3 months postoperatively. Allocation of the participants to one of the two treatment groups is done intraoperatively after initial incision has been made. Participants as well as the research coordinator handling the collected questionnaires postoperatively and evaluating wound healing are all unaware of which method was used for skin closure.
Recruitment of participants to this project is expected to begin in September 2015 or as soon as permission from the Regional Ethics Committee and the Danish Data Protections Agency is obtained. A total of 30 participants are to be included at our institution. Recruitment is expected completed after a maximum period of 1.5 years. The project is expected to be completed 1 year after recruitment of the last participant (2018).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Regular | No intervention | –Regular closure: The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. |
| Additional tissue adhaesive | Experimental | Device: tissue adhesive (Leukosan®)The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Patient > 18 years of age.
- Patients determined to be suitable for primary simultaneous bilateral TKA based on physical exam and medical history including the following:
- o Osteoarthritis (OA)
- Patient is skeletally mature.
- Patient is willing and able to provide written informed consent.
Key exclusion criteria (4 listed)
- Patients with previous open knee surgery on either knee (i.e., osteotomy, unicompartemental arthroplasty, osteosynthesis)
- Patients with previous major trauma to either knee resulting in deformity og scarring.
- Patients receiving treatment for DVT or PE postoperatively.
- Patients with known allergy to skin adhesives
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tissue adhesive (Leukosan®)Tissue ahaesive | Device | Additional tissue adhaesive |
Primary outcome
Wound discharge during stay
Time frame: 3 days post op
The wound will be defined as actively oozing, if the standard bandage Mepilex Border Post-op®, is soaked to the border. Bandages soaked to the border will be replaced. Number of replaced bandages for each knee will be recorded.
1 secondary outcome
ASEPSIS score
Time frame: 3 weeks post op
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Total Knee Arthroplasty
RecruitingPhase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Venous Thromboembolism (VTE)
Recruiting
SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty
Knee Osteoarthritis
Enrolling by invitationObservational study
Persona SoluTion PPS Femur PMCF
Rhematoid Arthritis, Osteo Arthritis of the Knee
Recruiting
ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty
Knee Osteoarthritis
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing tissue adhesive (Leukosan®) in people with Total Knee Arthroplasty and Infection, run by Hvidovre University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wound discharge during stay (time frame: 3 days post op). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2019.